WeVote
Log In

Bill

Bill

SB 1076

newborn screening; Duchenne muscular dystrophy

57th Legislature - First Regular Session Introduced by Selina Bliss and 4 co-sponsors

Arizona bill mandates newborn screening for Duchenne muscular dystrophy to enable early detection and treatment of this severe genetic muscle disorder.

DPA
0
WeVote Research Nonpartisan
Bill Summary · SB 1076

Legislative bill overview

SB 1076 would require Arizona to add Duchenne muscular dystrophy (DMD) to its newborn screening program. Currently, Arizona screens newborns for dozens of conditions but does not include DMD, a severe genetic disorder affecting muscle development. The bill mandates implementation of screening protocols to identify affected infants early.

Why is this important

Early detection of DMD allows families to begin treatment and management immediately, potentially improving outcomes and quality of life. DMD is a progressive, life-threatening condition where early intervention with medications like corticosteroids and newer gene therapies can slow disease progression. This expands access to preventive healthcare for Arizona's most vulnerable population—newborns who cannot advocate for themselves.

Potential points of contention

  • Cost and resource allocation: Adding screening requires funding for testing infrastructure, equipment, and trained personnel; questions exist about burden on state laboratories and healthcare budgets
  • Treatment availability gap: Screening only matters if families can access treatments; Arizona would need to ensure affordability and availability of DMD therapies, particularly expensive gene therapies
  • False positives and anxiety: Newborn screening can produce false positive results, potentially causing parental distress before confirmatory testing clarifies diagnosis

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.